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Abstract
Background: Single embryo transfer (SET) has been utilized as a strategy to reduce the chance of multifetal
gestations in in vitro fertilization (IVF) but lower pregnancy rate remains a concern. Recent studies showed that
favorable outcome regarding SET can be achieved by selecting embryos with “more normal” genetic components.
We explored the use of rapid array comparative genomic hybridization (aCGH) to select blastocysts for fresh SET
and compared with the protocols adopting vitrified (ultrarapidly frozen) embryo transfer cycle. Validation of the
rapid protocol of aCGH and comparison of the result with the regular protocol of aCGH and next generation
sequencing (NGS) are also performed.
Results: First-time IVF patients with normal karyotype (n = 21) were enrolled for elective fresh SET cycle (n = 8;
designated as fresh SET group) or vitrified embryo transfer cycle (n = 13; designated as vitrified ET group) coupling
with comprehensive chromosomal screening by a 9-h rapid aCGH from Day 5 trophectoderm (TE) biopsy. In fresh
SET group, 86 blastocysts (10.8 blastocysts/patient) were biopsied and analyzed. Aneuploidy was detected in 53.5 %
(46/86) of the biopsied blastocysts. All patients had a single embryo transferred on the following day. The clinical
pregnancy rate was 87.5 % (7/8) and the ongoing pregnancy rate was 62.5 % (5/8). In vitrified ET group, 58
blastocysts (4.5 blastocysts/patient) were biopsied and 56 blastocysts were analyzed. Aneuploidy was detected in
39.3 % (22/56) of biopsies. The patients accepted for SET or double embryos transfer (DET) in non-stimulated cycles.
The clinical pregnancy rate and the ongoing pregnancy rate was 76.9 % (10/13) and 53.8 % (7/13) respectively.
Spontaneous abortions occurred in both of the two patient groups. In the series of fresh SET group, no twin
pregnancy was noted and at least one healthy baby had been born at gestational age (GA) 37+6 weeks when
submission. The results of PGS by rapid aCGH, regular aCGH and NGS were comparable in most occasions.
Conclusion: This study evaluates the use of rapid aCGH to select blastocysts for fresh SET and demonstrates its
feasibility in a real clinical IVF program. A successful livebirth is achieved and the favorable outcome is superior to
the protocol adopting vitrified ET cycle in our own setting. Additional studies are needed to verify this pilot data
and validate its application in large randomized trials.
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Background
Preimplantation genetic screening (PGS) has been con-
sidered a feasible strategy, by reducing the probability of
transferring the aneuploid embryos during in vitro
fertilization (IVF), in improving the implantation rate as
well as the livebirth rate in the practice of artificial re-
productive technology (ART) for decades [1]. However,
a much wider acceptance by the academic community
does not occur until recently, by some recent seminal
studies which allowed us to have a more comprehensive
understanding of the critical points in the whole IVF-
PGS process [2–5]. The famous “Mastenbroek contro-
versy” published in 2007 stating that for women with
advanced maternal age, the livebirth rate of the PGS
group was poorer than the non-PGS group did raise a
huge concern for the validity of PGS and the traditional
PGS by fluorescence in situ hybridization (FISH) was al-
most abandoned [6, 7]. However, more and more recent
studies had made us known that the ironic outcome re-
vealed by that randomized study may be due to the limi-
tations of the genetic tool used for PGS itself (FISH), as
well as the timing of the biopsy was set at the cleavage
stage embryos (Day 3). The outcomes of PGS, especially
the most important livebirth rate, are at least greatly af-
fected by three critical parameters: the timing of biopsy,
the genetic tools used for PGS, and to freeze or not to
freeze the biopsied embryos [8–12]. After 2007, since
the emergence of many new technologies available for
genetic investigation, researchers are keen to verify and
validate the new tools when being used in PGS [5, 13–15].
Nowadays it is a reality to use the latest technology such
as array comparative genomic hybridization (aCGH) and
next generation sequencing (NGS) platforms to screen the
embryos because of the advancement of a critical tech-
nique called whole genome amplification (WGA). The
aCGH and NGS had become accessible for PGS after
WGA [15–19]. However, such amplification may also
introduce errors and thereby other research groups had
heartily advocated for WGA-free quantitative polymerase
chain reaction (qPCR) based rapid diagnosis [8, 11, 20].
Excellent results were achieved by even using single em-
bryo transfer (SET) in fresh cycle by the group led by
Richard Scott Jr and Nathan Treff based in US [11], and
even with a limited set of chromosomes being tested by
our group [21].
It is now understood that the blastomere biopsy at
Day 3 cleavage-stage embryos may impair the implant-
ation potential while the trophectoderm (TE) biopsy at
Day 5/6 blastocysts may not [3]. However, due to the
sophistication of the genetic tools used to screen the de-
veloping embryos, it is not always feasible to have the
report turnout time to be less than one day, since all
embryos must not survive in vitro after 7 days post-
fertilization unless being frozen. Therefore in before for
all amplification-based technologies, including aCGH
and NGS, it is not feasible to do fresh embryo transfer if
the timing of the biopsy was set at Day 5/6. Earlier stud-
ies did report some cycles based upon PGS by aCGH on
Day 3 embryos [10, 22–24], but very few at Day 5/6 be-
cause the protocol of aCGH usually needs at least 2–3
days, in which the time for analysis was not counted in
[25]. To freeze the biopsied embryos sent for PGS, and to
transfer the thawed euploid embryos in non-stimulated
cycles, becomes the standard practice for most IVF-PGS
centers. Recently, some researchers showed that the com-
bination of PGS and embryo vitrification (ultrarapid
freeze) can produce better clinical outcomes compared to
non-PGS ET [26] while we considered fresh ET remains a
preferred choice in routine IVF if a rapid PGS is feasible.
Quite recently the newest protocol of rapid aCGH an-
alyzes suited for PGS was available, and therefore, we
conducted this pilot study to evaluate its feasibility in
a real clinical setting: TE biopsy on Day 5, 9-h aCGH
analysis, followed by fresh SET on Day6. Additionally,




A total of 21 patients were subjected to in IVF-rapid
PGS aCGH treatment, including 8 patients with fresh
SET (fresh SET group) and 13 patients with vitrified
SET/DET (vitrified ET group) (Table 1). The average age
of the patients was 36.0 years (range of 29–42 years),
with a mean age of 33.6 years (range of 29–37 years) in
fresh SET group and 37.5 years (range of 34–42 years) in
vitrified ET group. In fresh SET group, 86 blastocysts
(10.8 blastocysts/patient) were biopsied and analyzed.
Euploidy was found in 46.5 % (40/86) of the embryos,
whereas chromosome abnormalities were found in the
remaining 53.5 % (46/86) of embryos (Table 1). Among
the aneuploid blastocysts, 43.5 % (20/46) had single
chromosomal abnormality [of which. 35.0 % (7/20) dis-
played single chromosome loss, 15.0 % (3/20) displayed
single chromosome gain and 50.0 % (10/20) displayed
single segmental aneuploidy with an aberration between
6.4 Mb and 85.9 Mb], 21.7 % (10/46) had dual chromo-
somal abnormalities and 34.8 % (16/46) had severe,
compound genetic defects involving in three or more
chromosomes (Table 2 and Fig. 1). Look at the single-
chromosome level, 143 chromosome abnormalities,
including 82 whole chromosome gain/loss and 61 seg-
mental aneuploidies, were found in the 46 aneuploid
embryos (Fig. 2a). In vitrified ET group, a total of 58
blastocysts (4.5 blastocysts/patient) were biopsied. Of
which, two blastocysts failed with WGA and thus finally
56 blastocysts were analyzed. Euploidy and aneuploidy
were detected in 60.7 % (34/56) and 39.3 % (22/56) of
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biopsies respectively (Table 1). Among the aneuploid
blastocysts, 59.1 % (13/22) had single chromosomal
abnormality [of which. 30.8 % (4/13) displayed single
chromosome loss, 15.4 % (2/13) displayed single
chromosome gain and 53.8 % (7/13) displayed single
segmental aneuploidy with an aberration between
12.3 Mb and 75.4 Mb], 13.6 % (3/22) had dual chromo-
somal abnormalities and 27.3 % (6/22) had severe, com-
pound genetic defects involving in three or more
chromosomes (Table 2). In the single-chromosome level,
51 chromosome abnormalities, including 20 whole
chromosome gain/loss and 31 segmental aneuploidies,
were found in the 22 aneuploid embryos (Fig. 2b). Over-
all, the aneuploidy rate of the 142 embryos examined
was 47.9 % (68/142). Chromosome abnormalities were
detected in all chromosomes where genetic defects in-
volving chromosome 5, 15, 19, 22 and X were most fre-
quently observed while errors in chromosome 2, 9, 12,
17, 20 and 21 seen relatively uncommon (Fig. 2c). The
diagnostic results were validated by regular aCGH and
NGS (see the Methods section and Fig. 3). The rate of
correct diagnosis was 100 % in all embryos. The positive
and negative predictive rates of rapid aCGH in our series
were thus 100 %.
Clinical outcome
In both of fresh SET and vitrified ET group, all patients
had at least one euploid embryo available for fresh trans-
fer on Day 6 (fresh SET group) or in non-stimulated cy-
cles (vitrified ET group). Combining the data of rapid
aCGH and blastocyst grading, the best-graded euploid
embryo(s) were chosen for ET for each of the patients.
In fresh SET group, the clinical pregnancy rate was
87.5 % (7/8) and the ongoing pregnancy rate was 62.5 %
(5/8). Spontaneous abortions occurred in two patients at
GA 5 and GA 4 weeks (the genetic analysis cannot be
Table 1 Summary of rapid aCGH results for 86 embryos from 8 patients accepted for fresh single embryo transfer (SET) and 58












Total WGA failure Euploid Aneuploid
I. Fresh SET
1 29 10 0 1 9 SET Yes Live birtha (at GA = 37+6 weeks)
2 33 9 0 4 5 SET Yes Abortion (at GA = 5 weeks)
3 34 14 0 3 11 SET No —
4 34 14 0 6 8 SET Yes Ongoing pregnancy (GA = 37 weeks)
5 37 13 0 7 6 SET Yes Ongoing pregnancy (GA = 13 weeks)
6 34 9 0 5 4 SET Yes Abortion (at GA = 4 weeks)
7 37 9 0 8 1 SET Yes Ongoing pregnancy (GA = 16 weeks)
8 31 8 0 6 2 SET Yes Ongoing pregnancy (GA = 7 weeks)
Overall 86 0 40 46
II. Vitrified ET
1 41 3 0 1 2 SET Yes Live birth (at GA = 39 weeks)
2 40 4 0 1 3 SET Yes Termination (acardiac monster) (at GA = 14+4 week)
3 34 4 0 3 1 SET Yes Ongoing pregnancy (GA = 19+4 week)
4 39 5 0 1 4 SET Yes Ongoing pregnancy (GA = 22 week)
5 42 3 0 2 1 DET No —
6 37 6 0 5 1 DET Yes Live birth (at GA = 38 weeks)
7 36 5 0 4 1 DET Yes Live birth (at GA = 37 weeks)
8 37 5 0 2 3 DET Yes Abortion (at GA = 8+3 weeks)
9 42 5 0 2 3 DET No —
10 37 3 0 3 0 DET Yes Ongoing pregnancy (GA = 16 week)
11 34 5 0 5 0 DET No —
12 34 5 0 3 2 DET Yes Abortion (at GA = 10+6 weeks)
13 35 5 2 2 1 DET Yes Ongoing pregnancy (GA = 12+3 weeks)
Overall 58 2 34 22
aSingle birth (3040 g; AS 8 > 9) by C-section due to breech presentation
WGA whole genome amplification, GA gestational age
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performed due to the spontaneous expulsion of the ges-
tational tissue). No twin pregnancy was noted in this
series and at least one healthy baby had been born at
GA 37+6 weeks (Table 1). In vitrified ET group, the clin-
ical pregnancy rate and the ongoing pregnancy rate was
76.9 % (10/13) and 53.8 % (7/13) respectively. Spontan-
eous abortions occurred in two patients at GA 8+3 and
GA 10+6 weeks. One fetus was terminated at GA 14+4
weeks due to acardiac monster. Genetic analysis by
aCGH for tissues from the aborted and terminated fe-
tuses revealed no specific finding; all cases had a normal
karyotype.
Discussion
PGS has become a well-established tool in the practice
of IVF nowadays with the development of many sophis-
ticated tools used for investigating the genetic comple-
ments of the embryos before being transferred [14, 27].
However, the major difficulty in these genetic tools, such
as the latest NGS, is the complexity of analytical pipe-
lines [28]. Therefore to freeze the embryos to earn more
time for the reliable analysis of the PGS results remains
the mainstream in most PGS centers, especially those in-
volving aCGH and NGS [19]. It is now known that the
biopsy timing will be better at Day 5/6 blastocyst stage
instead of Day 3 cleavage-stage embryos in regard to the
implantation potential [3], and this new finding creates
an even more difficulty: the time span of analysis if we
want to do it in fresh transfer will be shortened from
3 days to 1 day, which rendered the analysis of aCGH
and NGS almost impossible. Up to this submission,
there are very few reports achieving this goal when using
high-complexity-tool such as aCGH or NGS and also
successfully conducted the fresh SET [25, 29].
In order to facilitate the analytical bioinformatics pipe-
lines used in aCGH and NGS, some resolution was
sacrificed for efficiency and also because of the process
of WGA may introduce errors, and some leading groups
Table 2 Details of rapid aCGH results of aneuploid blastocysts derived from 8 patients for fresh SET and 13 patients for vitrified ET











1 9 4 (44.4 %) [1/2/1] 2 (22.2 %) 3 (33.3 %)
2 5 3 (60.0 %) [1/1/1] 0 (0 %) 2 (40.0 %)
3 11 2 (18.2 %) [1/0/1] 5 (45.5 %) 4 (36.4 %)
4 8 3 (37.5 %) [0/0/3] 1 (12.5 %) 4 (50.0 %)
5 6 4 (66.7 %) [3/0/1] 0 (0 %) 2 (33.3 %)
6 4 2 (50.0 %) [0/0/2] 2 (50.0 %) 0 (0 %)
7 1 1 (100.0 %) [0/0/1] 0 (0 %) 0 (0 %)
8 2 1 (50.0 %) [1/0/0] 0 (0 %) 1 (50.0 %)
Overall 46 20 (43.5 %) [7/3/10] 10 (21.7 %) 16 (34.8 %)
II. Vitrified ET
1 2 1 (50.0 %) [1/0/0] 0 (0 %) 1 (50.0 %)
2 3 2 (66.7 %) [0/0/2] 1 (33.3 %) 0 (0 %)
3 1 1 (100.0 %) [0/0/1] 0 (0 %) 0 (0 %)
4 4 2 (50.0 %) [1/1/0] 1 (25.0 %) 1 (25.0 %)
5 1 1 (100.0 %) [0/1/0] 0 (0 %) 0 (0 %)
6 1 1 (100.0 %) [0/0/1] 0 (0 %) 0 (0 %)
7 1 1 (100.0 %) [0/0/1] 0 (0 %) 0 (0 %)
8 3 2 (66.7 %) [0/0/2] 0 (0 %) 1 (33.3 %)
9 3 1 (33.3 %) [1/0/0] 1 (33.3 %) 1 (33.3 %)
10 0 0 (0 %) [0/0/0] 0 (0 %) 0 (0 %)
11 0 0 (0 %) [0/0/0] 0 (0 %) 0 (0 %)
12 2 1 (50.0 %) [1/0/0] 0 (0 %) 1 (50.0 %)
13 1 0 (0 %) [0/0/0] 0 (0 %) 1 (100.0 %)
Overall 22 13 (59.1 %) [4/2/7] 3 (13.6 %) 6 (27.3 %)






Fig. 1 Representative rapid aCGH results of blastocysts obtained by trophectoderm biopsy at post-fertilization Day5 showed a euploid chromo-
somes [arr(1–22) × 2,(XY) × 1], b a segmental aneuploidy [arr 5q15q35.3(94,800,050-180,684,501) × 1] and c a complex chromosomal abnormality
[arr(1,3-15,17-22) × 2,(2) × 1,(16) × 1,(X) × 1]. Arrow indicated the aneuploidy chromosome or chromosomal fragment. The reference DNA used for
aCGH was whole genome amplification product of a normal male embryo DNA
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admitted it is now available for PGS to use these fancy
technologies in a “low-pass” strategy [18].
It is now well known that mosaicism is a common
phenomenon in the development of early human em-
bryos [30], and therefore whether the “best” embryo can
really be selected with the most sophisticated genetic
tools remains in doubt. Another group thus proposed
for amplification-free quantitative polymerase chain re-
action (qPCR) based PGS strategy, which only detects
the copy number changes involving the whole chromo-
somal arm level, and surprisingly the result was
excellent. They published a series of excellent data to
demonstrate that by using qPCR, the accuracy was com-
parable to aCGH [8, 15, 20], the implantation rate and
delivery rate were also excellent [2, 4], and such impres-
sion even was validated in a randomized trial concerning
delivery rate and neonatal/obstetrical outcome (the
BEST trial) [11].
Regarding the aneuploidies detected by rapid aCGH in
this pilot study, the overall aneuploidy rate was 47.9 %
(53.5 % in fresh SET group and 39.3 % in vitrified ET
group), which is similar to a recent series comparing
aCGH and NGS (which is around 60 %, see Yang et al.,
2015 [19]), and was considered to be a result that both
of the analyses included segmental aneuploidies greater
than 5 Mb (in Yang’s series, they reported a 42 Mb gain
on 16q and a 16 Mb loss on 18q). The cytogenetic ab-
normalities distributed in all 24 chromosomes. However,
in a recent validation study to compare NGS and aCGH
to detect the cytogenetic abnormalities in the TE cells of
human embryos, the resolution has been greatly en-






















































































Fig. 2 Chromosomal abnormalities, at the single-chromosome level, detected by rapid aCGH in a 86 embryos from 8 patients accepted for fresh
SET, b 58 embryos from 13 patients choosing vitrified ET, and c all 144 embryos from the 21 patients. A total of 194 chromosome abnormalities
(143 in in fresh SET group and 51 in vitrified ET group), including 102 whole chromosome gain/loss and 92 segmental aneuploidies, were found
in 68 aneuploid embryos
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aCGH and NGS must be much higher than qPCR
(which only detects aneuploidy in a chromosomal arm
level and the aneuploidy rate was around 30 %, see For-
man et al., 2014 [11]), however, it has been noted that
aCGH may have a higher false positive rate than qPCR
[20], in which some euploid embryos may be sacrificed
and not transferred. Our report is one of the very few
studies up to 2016 (and the first report from Taiwan)
adopting Day 5 blastocysts biopsy, 9-h aCGH and fresh
SET to achieve successful singleton livebirth. Further-
more, the favorable outcome in terms of the clinical
pregnancy rate and the ongoing pregnancy rate is super-
ior to the protocol adopting vitrified ET cycle (87.5 and
62.5 % in fresh SET group, and 76.9 % and 53.8 % in vit-
rified ET group). We admit the case number is very
small (n = 8 in fresh SET group and n = 13 in vitrified ET
group) and it is only a pilot study which needs further
validation in a prospective, large-scale and better be ran-
domized study to explore its real efficacy.
However, despite in theory the resolution of NGS
should be much better than aCGH in picking up
aberrations in genetic complements. The current “low-
pass strategy” adopted by NGS made it only comparable
to the aCGH platform when using in PGS [19, 31, 32].
With the advance of bioinformatics pipelines it can be
expected that NGS can pick up more aneuploidies than
aCGH, as well as the turn-around time for analysis
should be greatly shortened, to make fresh embryo
transfer feasible in the near future. When three compet-
ing PGS tools (qPCR, aCGH and NGS) can all produce
results in one single day, then it is possible to conduct a
real randomized trial to compare the efficacy and may
further enhance our understanding of the early develop-
ment of human embryos, and to improve the whole
IVF-PGS process.
It is noteworthy that despite it was thought that
freeze-thaw process might damage the embryos whereas
a growing number of epidemiological studies had sug-
gested otherwise: that an increased rate of adverse peri-
natal outcomes such as low birth weight was noted in
fresh IVF cycles compared with frozen embryo transfer
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Fig. 3 Exemplified PGS results by use of rapid aCGH (DNA hybridization for 2 h), regular aCGH (DNA hybridization for 16 h) and next generation
sequencing (NGS) for the same WGA products. Rapid and regular aCGH were performed with CytoScan 60 K microarray chip (Agilent customer
array, Changhua Christian Hospital, Taiwan) on a G4900DA SureScan microarray scanner (Agilent Technologies, CA, USA). NGS was performed
using Ion PGM Hi-Q Sequencing Kit with Ion 316 chip (Life technologies, California, USA) on the Ion Torrent PGM Instrument (Life technologies)
platform. Aneuploidy chromosomes or chromosomal fragments are indicated by arrows. Some atypical segmental gains and/or losses with copy
number change < 1 but > 0.5 (a likely result of embryo mosaicism) were also classified as segmental aneuploidies and marked by stars. The results
of rapid aCGH are comparable with that of regular aCGH and NGS
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impact upon endometrial receptivity and therefore fro-
zen embryo transfer cycles should be considered in
those high-responders [33]. However, we considered that
if in the future time constraint is no longer considered a
problem when the advantage and safety of frozen ET cy-
cles are well established [34], the effort should be placed
upon improving the bioinformatics pipelines of NGS
from “low-pass-strategy” into an algorithm with a better




During January of 2014 to December of 2015, 21 infer-
tile couples visited the clinic center for their first-time
IVF and elected either fresh SET (n = 8; designated as
fresh SET group) or vitrified SET/DET (n = 13; desig-
nated as vitrified ET group) by conjugation with compre-
hensive chromosomal screening via a 9-h rapid PGS
aCGH protocol for trophectoderm (TE) biopsy on Day
5. All the couples have a normal karyotype and the pa-
tients are expected to have a good prognosis (female
age ≤ 42 years, no prior miscarriage and no remarkable
personal and family history). After pre-treatment
counseling was provided, all the 21 couples agreed to
participate in this study and signed an informed con-
sent prior to the sample collection and evaluation.
The study was approved by the Ethics Committees of
Changhua Christian Hospital, Changhua, Taiwan and
adhered to the guidelines approved by the Institu-
tional Review Board.
Fertilization, embryo culture and TE biopsy
Intracytoplasmic sperm injection (ICSI) was performed
following the removal of cumulus cells and the presence
of two pronuclei and two polar bodies 16–18 h after in-
jection was ascertained normal fertilization. Fertilized
embryos were cultured in sequential media (Sage, CA,
USA) to the blastocyst stage. On Day 3, a laser-created
narrow channel was made in the zona pellucida of all
embryos. On Day 5, fully differentiated embryos were
biopsied using suction to gently extrude and pull 3–8
TE cells from blastocysts. The biopsied cells were
washed in 1X PBS (catalog no. 70013–032) (Gibco by
life technology, CA, USA) and collected into a micro-
centrifuge tube with 2.5 μl 1X PBS (Gibco by life tech-
nology). The cells were used directly for whole genome
amplification (WGA).
Rapid aCGH
The WGA was performed using REPLI-g Single Cell Kit
(Qiagen, Hilden, Germany) and following the manufac-
turer’s instructions. Amplified DNA was purified using
the QIAamp DNA Blood Mini Kit (Qiagen). The DNA
purities and concentrations were examined by Nanodrop
2000 spectrophotometer (Thermo Fisher Scientific,
Delaware, USA). Approximately 1 μg of purified DNA
was fluorescently labeled with Cy3 d-CTP or Cy5-dCTP
using SureTag DNA Labeling Kit (Agilent Technologies,
CA, USA) and then cleaned up by Microcon YM-30
centrifugal filter unit (Millipore, MA, USA). The yield
DNA was hybridized with CytoScan 60 K microarray
chip (Agilent customer array, Changhua Christian Hos-
pital, Taiwan) at 65 °C for 2 h. The image on a chip was
acquired with a G4900DA SureScan microarray scanner
(Agilent Technologies, CA, USA) and analyzed with
Agilent Genomic Workbench software (Agilent Tech-
nologies) for DNA gain or loss across all 24 chromo-
somes. Aberrations were detected by using default
setting with an algorithm of z-score conjugated with a
filter of a minimum of 5 Mb aberrations. All aCGH pro-
cedures were completed within 9 h, allowing rapid
evaluation of the TE biopsies and providing a feasible
opportunity for fresh embryo transfer on the following
day, Day 6.
Regular aCGH
To evaluate the reliability of rapid aCGH, WGA prod-
ucts of all the biopsied blastocysts were processed for
the regular aCGH analysis. All procedures of regular
aCGH analysis are the same as that described in rapid
aCGH, except for the DNA-chip probes hybridization
duration which was extended (from 2 h) to 16 h.
NGS
WGA products of all the biopsied blastocysts were also
processed for the NGS analysis in order to evaluate the
reliability of rapid aCGH and compare the performances
of difference platforms (i.e. rapid aCGH, regular aCGH
and NGS). Approximately 1 μg of WGA DNA was used
for library construction using Ion Xpress Plus gDNA
Fragment Library Preparation Kit Set (Life technologies,
California, USA) and following the manufacturer’s in-
structions. The quantity of library was determined using
Qubit dsDNA HS assay kits (Life technologies) with
Qubit fluorometer (Life technologies). The template-
positive Ion Sphere Particles (ISPs) were generated
using Ion PGM Hi-Q Template Kits (Life technolo-
gies) with the Ion OneTouch 2 Instrument (Life tech-
nologies) and then enriched with the Ion OneTouch
ES Instrument (Life technologies). Sequencing was
performed on the Ion Torrent PGM Instrument (Life
technologies) platform using the Ion PGM Hi-Q Se-
quencing Kit and Ion 316 chip (Life technologies).
PGS analysis for aneuploidy detection was performed
by the Ion Reporter Server System (https://ionreporter.
thermofisher.com/ir/).
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Embryo selection for transfer
Only euploid blastocyst ascertained by rapid aCGH ana-
lysis was selected for transfer. When multiple euploid
blastocysts are available, the best grade one was chosen
for transfer. Embryo grading is based on the principle
proposed in Sakkas and Gardner (2005) [35]. In brief,
the blastocyst is given a grade based on three main com-
ponents of the embryo: (1) expansion degree and hatch-
ing status, (2) the inner cell mass (ICM) development,
and (3) the TE cell quality. The graded embryo is given a
number grade (1–6), followed by a letter grade for the
ICM and then the TE (A, B or C). All embryos, which
were classified as aneuploid, were confirmed again by
aCGH before discarded.
Conclusions
In this study, we demonstrate the results of aCGH (in-
cluding rapid and regular protocol) and NGS (regular
protocol) being used for PGS are comparable to each
other with high consistency. Furthermore, we also dem-
onstrate the feasibility of using rapid protocol aCGH to
select blastocysts for fresh SET in a real clinical IVF set-
ting, in which at least one successful live-birth has
already been achieved. Meanwhile, in terms of the clin-
ical pregnancy rate as well as the ongoing pregnancy
rate, PGS by aCGH followed by fresh cycle ET seems su-
perior (or at least comparable) to PGS by aCGH coupled
with vitrified cycle ET. Additional studies are needed to
verify this pilot data and validate its clinical utility in
large prospective randomized trials.
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